Active Ingredient: Fosaprepitant
Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in paediatric patients aged 6 months and older.
For this indication, competent medicine agencies globally authorize below treatments:
Intravenous, between 2 milligrams fosaprepitant per kilogram of body weight and 4 milligrams fosaprepitant per kilogram of body weight, once daily.
The recommended dose is 150 mg administered as an infusion over 20-30 minutes on Day 1, initiated approximately 30 minutes prior to chemotherapy. Fosaprepitant should be administered in conjunction with a corticosteroid and a 5-HT3 antagonist as specified in the tables below.
The following regimens are recommended for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy.
Table 1. Recommended dosing for the prevention of nausea and vomiting associated with highly emetogenic chemotherapy regimen in adults:
| Day 1 | Day 2 | Day 3 | Day 4 | |
|---|---|---|---|---|
| Fosaprepitant | 150 mg intravenously | none | none | none |
| Dexamethasone | 12 mg orally | 8 mg orally | 8 mg orally twice daily | 8 mg orally twice daily |
| 5-HT3 antagonists | Standard dose of 5-HT3 antagonists. |
Dexamethasone should be administered 30 minutes prior to chemotherapy treatment on Day 1 and in the morning on Days 2 to 4. Dexamethasone should also be administered in the evenings on Days 3 and 4. The dose of dexamethasone accounts for active substance interactions.
Table 2. Recommended dosing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy regimen in adults:
| Day 1 | |
|---|---|
| Fosaprepitant | 150 mg intravenously |
| Dexamethasone | 12 mg orally |
| 5-HT3 antagonists | Standard dose of 5-HT3 antagonists. See the product information for the selected 5-HT3 antagonist for appropriate dosing information |
Dexamethasone should be administered 30 minutes prior to chemotherapy treatment on Day 1. The dose of dexamethasone accounts for active substance interactions.
It should be administered as an infusion over 20-30 minutes.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
